Coverage of drugs included in Florida Blue’s Responsible Steps Program is contingent on documented prior medication trials. For antidepressant target drugs, the policy generally requires prior trials of two or more generic versions from the listed antidepressant options (examples include bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine/venlafaxine ER, and vilazodone). (See the program’s therapeutic-category authorization form for the full target list.)
When the requested indication is pain-related rather than primary antidepressant treatment, indication‑specific prerequisite lists apply: for neuropathic pain the prior-use requirement is previous trial of one of the listed agents (for example, amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline); for fibromyalgia the prior-use list includes agents such as amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol; and for chronic musculoskeletal pain prerequisite options include acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, an NSAID (oral or topical), or tramadol. These indication-specific alternatives satisfy the program prerequisite when the target drug is being used for that condition.
For many antipsychotic target drugs the policy requires prior trials of two or more generic antipsychotics from the enumerated list (examples: aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone). An explicit exception is Lybalvi, which requires documentation of only one prior generic antipsychotic instead of two.
Gabapentin extended‑release (ER) products (Gralise, generic Gralise, Horizant) are included in the program; prior documented use of generic immediate‑release gabapentin is noted as a prerequisite in the program language where gabapentin ER is the requested product.
Providers seeking authorization must submit clinical documentation showing the prior medication trials appropriate to the indication (the number of distinct generic trials depends on the target drug and its class — typically 2 or more generics for many antidepressant/antipsychotic targets, with the Lybalvi exception: 1 generic). Failure to document the required prior trials may result in denial of authorization.